|
| Press Releases |
|
 |
|
| Saturday, August 24, 2024 |
|
|
日本厚生勞動省批准了莫德納公司針對SARS-COV-2 JN.1變異株的COVID-19 mRNA疫苗的部分變更申請 |
| Moderna, Inc.（納斯達克股票代碼：MRNA）今日宣佈，已獲得日本厚生勞動省（MHLW）批准其COVID-19 mRNA疫苗Spikevax更新配方的部分變更申請，該疫苗針對SARS-CoV-2 JN.1變異株。 more info >> |
|
|
日本厚生劳动省批准了莫德纳公司针对SARS-COV-2 JN.1变异株的COVID-19 mRNA疫苗的部分变更申请 |
| Moderna, Inc.（纳斯达克股票代码：MRNA）今日宣布，已获得日本厚生劳动省（MHLW）批准其COVID-19 mRNA疫苗Spikevax更新配方的部分变更申请，该疫苗针对SARS-CoV-2 JN.1变异株。 more info >> |
|
|
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1 |
| Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1. more info >> |
|
| Tuesday, March 26, 2024 |
|
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine |
| Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. more info >> |
|
| Monday, December 11, 2023 |
|
|
Moderna公司回顧了在第二次環境、社會和治理（ESG）投資者活動中取得的進展和雄心 |
| more info >> |
|
|
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event |
| more info >> |
|
| Wednesday, July 5, 2023 |
|
|
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 |
| Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. more info >> |
|
| Wednesday, May 3, 2023 |
|
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
| Tuesday, September 13, 2022 |
|
|
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines |
| PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
佐藤木工、宝珠悉皆師（ほうじゅしっかいし）の那須勲氏と東京銀座において、「二人展 唯装論〜聖なる虚飾〜」を開催
Mar 12, 2026 08:00: JST
|
|
|
テンストレント、完全オープンソーススタックを搭載した初のRISC-V AIワークステーション「TT-QuietBox(TM) 2」を発表。テラフロップス級推論を実現
Mar 12, 2026 01:00: JST
|
|
|
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference
Mar 12, 2026 01:00: JST
|
|
|
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference
Mar 12, 2026 00:00 HKT/SGT
|
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 11, 2026 20:15: JST
|
|
|
Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025
Mar 11, 2026 19:16 HKT/SGT
|
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 11, 2026 20:15 JST
|
|
|
云顶新耀维适平(R)中国大陆首张处方落地 填补中重度溃疡性结肠炎治疗空白
Mar 11, 2026 19:15 HKT/SGT
|
|
|
雲頂新耀維適平(R)中國大陸首張處方落地 填補中重度潰瘍性結腸炎治療空白
Mar 11, 2026 19:15 HKT/SGT
|
|
|
越秀房產基金經營保持韌性 2025年收入逾人民幣18億元
Mar 11, 2026 19:00 HKT/SGT
|
|
|
越秀房产基金经营保持韧性 2025年收入逾人民币18亿元
Mar 11, 2026 18:38 HKT/SGT
|
|
|
MarketingPulse and eTailingPulse open next Thursday
Mar 11, 2026 16:54 HKT/SGT
|
|
|
エーザイ、アルツハイマー・パーキンソン病学会（AD/PD 2026）において、レカネマブの長期実臨床治療をはじめとするアルツハイマー病の最新知見を発表
Mar 11, 2026 11:30: JST
|
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 11, 2026 12:07 JST
|
|
|
JOYY Reports 4Q and FY2025 Financial Results: Q4 Revenue Returns to YoY Growth, BIGO Ads Up 61.5% YoY
Mar 11, 2026 09:40 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
